Create your Personal Health Record and unlock support built around you

Aligned with your diagnosis, treatment and where you are in your care. It lets HealthTree show you:

Treatments and trials you qualify for
Education for your stage of care
Financial support for your medications
Solutions to your side effects

Using all the Myeloma Tools in the Toolbox with Clifton C. Mo, MD Dana-Farber Cancer Institute

Posted on: Mar 12, 2024

Play Episode

Also available on

Spotify

Apple Podcasts

Youtube

Description

This show will not be live streamed. You can submit your questions in advance by clicking the button "Notify when available."

Learn from Clifton Mo, MD of Dana Farber Cancer Institute about the abundance of therapies for multiple myeloma and how/when they are used for treatment. While we have new and exciting CAR T and bispeicfic antibody therapies becoming more available for us, there are a host of other treatments that can be used for myeloma patients. Learn about these tools and those in clinical trials in this show.

Thanks to our episode sponsor, Karyopharm.

User uploaded media

Overview

Dr. Clifton Mo of Dana Farber Cancer Institue shares a multitude of tools available in the myeloma toolbox. This includes all of the "standard of care" drugs that we are familiar with such as immunomodulators, proteasome inhibitors, steroids, monoclonal antibodies as well as tools in development.

He reviews triplet combo treatment options at first relapse and his preference to use Kyprolis in the mix, especially when given a more aggressive myeloma.

Dr. Mo explains how antibody drug conjugates (ADCs) work and how the first ADC, BLENREP, may be making a comeback. He shares how dexamethasone can be reduced or stopped under certain conditions. He explains BCL-2 inhibitors like venetoclax and how they are making their way through clinical trials.

Dr. Mo describes celmods and how they work and are a promising new class of drugs. He also described how an XPO1 inhibitor called selinexor is being used both with the celmods and alone as an agent that works well for higher risk myeloma.

This shows myeloma patients how fortunate we are to have these tools available and speaks to the importance of having a myeloma specialist on your team who can help you make treatment decisions. This can be done alone or in partnership with your local oncologist. There is data that shows that having a specialist on year team leads to longer life.

On this episode

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Clifton C. Mo, MD

Dr. Mo received his medical degree from the Yale School of Medicine in 2004. He completed his internal medicine residency training at Walter Reed Army Medical Center in 2007 and his hematology/oncology fellowship training at the National Capital Consortium (Walter Reed/National Naval Medical Center) in 2010. He is board certified in hematology and medical oncology. Prior to joining the Jerome Lipper Multiple Myeloma Center at Dana-Farber in 2019, Dr. Mo spent 15 years as an active duty physician and officer in the United States Army, achieving the rank of Lieutenant Colonel. He spent over six years as a hematologic malignancy specialist at Walter Reed National Military Medical Center in Bethesda, Maryland, where he served as the autologous stem cell transplant program director and inpatient oncology medical director. He is also a veteran of the Operation New Dawn campaign of the Iraq War, where he received the Army Commendation Medal and was inducted into the Order of the Spur by the 5th Squadron, 4th Cavalry Regiment, for his service as a medical officer. Dr. Mo has over a decade of experience in treating patients with multiple myeloma. His clinical interests include novel therapeutics, the innate immune system and tumor microenvironment, autologous stem cell transplantation, and minimal residual disease detection.

Transcript

Using all the Myeloma Tools in the Toolbox with Clifton C. Mo, MD Dana-Farber Cancer Institute

Related Content